We recently compiled a list of the 10 Cheap Pharmaceutical Stocks to Buy According to Analysts. In this article, we are going to take a look at where Sanofi (NASDAQ:SNY) stands against the other ...

Some of the most high-profile acquisitions in recent years have involved women-fronted biotechs. BioSpace reviews five of the ...

French pharmaceutical giant Sanofi (NASDAQ: SNY) has announced its acquisition of UK-based biotech firm Vicebio in a deal ...

Sanofi is conducting a broad strategy review under Hudson, who took over as CEO on Sept. 1. He will give initial pointers on which businesses he wants to focus on at the investor day in Cambridge ...

Following the positive opinion by the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) on ...

The financing effort, spearheaded by Goldman Sachs and Morgan Stanley, forms part of Sanofi’s strategy to divest its $20 billion consumer health business.

– Bolsters clinical pipeline and adds near-term value creation opportunities – – Licenses proprietary masking platform with goal of minimizing off-tumor toxicity and offering expanded ...

Sanofi-aventis CEO Chris Viebacher outlined the research and development strategy that led to the purchase of Cambridge-based Genzyme Corp. for $20.1 billion and will lead the company to further ...